# Ritalin ### (methylphenidate hydrochloride, immediate-release) **[Ritalin](https://wiki.joshnp.com/books/drug-library/page/ritalin)** (methylphenidate hydrochloride, immediate-release); CII
[**Full Prescribing Information**](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a&type=display)[**DailyMed Drug Information**](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a)
--- ### **Summary** Ritalin is the immediate-release methylphenidate tablet, approved for ADHD in patients 6 years and older and for narcolepsy, and it is the reference product from which every long-acting methylphenidate is converted. Its short, sharply defined window is both its use and its cost: reversible within an afternoon and easy to schedule around, at the price of multiple daily dosing and a visible offset. Schedule II; brand and generic. --- ### **Forms & Strengths** - Tablets (10 mg and 20 mg partially bisected, 5 mg not scored): 5 mg, 10 mg, 20 mg --- ### **Dosing** - **Age:** - ADHD: >= 6y, and adults - Narcolepsy: no age floor - **Onset:** ~ 1 hour - **Duration:** 3 to 4 hours - **Initial Dose:** - >= 6 y/o and older: 5 mg twice daily, before breakfast and before lunch - Adults: 20 to 30 mg daily in 2 or 3 divided doses, 30 to 45 minutes before meals. - **Titration:** 5 - 10 mg every 7 days - **Max Dose:** 60 mg/day - **Considerations:** Give 30 to 45 minutes before meals, and the last dose before 6 p.m. The offset is abrupt and visible, which is the trade-off against every long-acting product. --- ### **Pharmacology** - **Mechanism:** Blocks presynaptic dopamine and norepinephrine reuptake at DAT and NET; does not meaningfully promote catecholamine release at therapeutic doses - **Delivery / Release:** Immediate release. Absolute bioavailability 22% d-enantiomer, 5% l-enantiomer; first-pass loss is large and stereoselective. No relevant food effect. - **Metabolism:** Esterase de-esterification to ritalinic acid, inactive. Not a CYP substrate. Protein binding 10% to 33%. Half-life 2.5 h in children, 3.5 h in adults; under 1% excreted unchanged. - **Class Positioning:** The reference immediate-release methylphenidate, and the product every long-acting conversion table is written from. Esterase clearance means renal and hepatic impairment barely change exposure, and elimination is not pH-dependent. --- ### **Indications** - **ADHD** (ICD-10: F90.0, F90.1, F90.2, F90.8, F90.9): patients 6 y/o and older, and adults - **Narcolepsy** (ICD-10: G47.419): no age floor is stated in this label --- ### **Off-Label Uses** - **ADHD in children 4 to 5 years old** (ICD-10: F90.x): behavioral parent training first line; IR methylphenidate where it fails and disturbance stays moderate to severe. Expert consensus. (AAP 2019) - **Afternoon top-up alongside a long-acting methylphenidate** (ICD-10: F90.x): coherent given the 3 to 4 hour window; the 60 mg/day ceiling applies to the sum. Limited data. (AHRQ 2024) - **Where the evidence does not support use:** treatment-resistant depression (F33.9), binge eating disorder (F50.2), cancer-related and chronic fatigue (R53.0, R53.83). Adult literature only; insufficient in children. (AHRQ 2024) - **Cognitive enhancement in a youth without ADHD:** not an indication and not supported. --- ### **Contraindications & Warnings** - **Boxed Warning:** Abuse, misuse and addiction, with overdose and death. Assess abuse risk before prescribing and reassess throughout treatment. - **Contraindicated:** - Hypersensitivity to methylphenidate or any component - MAOI use, current or within 14 days: hypertensive crisis - **Use with caution:** - Structural cardiac abnormality, cardiomyopathy, arrhythmia or coronary disease: avoid - Pre-existing hypertension: monitor blood pressure and pulse - Psychotic or bipolar disorder: exacerbation and treatment-emergent mania - Significant hyperopia or angle-closure risk: refer to ophthalmology - Personal or family history of tics or Tourette's syndrome - Substance use disorder in patient or household; an IR tablet is the most divertible methylphenidate form - **Screen before starting:** - Cardiac history and exam including family sudden death; the label requires no routine ECG - Tics, and risk factors for a manic episode - Abuse and diversion risk in patient and household - Baseline height, weight, blood pressure and heart rate --- ### **Drug Interactions** - **MAOIs** (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue): hypertensive crisis. Contraindicated within 14 days. - **Antihypertensives:** effectiveness reduced. Increase BP monitoring and adjust the antihypertensive. - **Halogenated anesthetics** (sevoflurane, isoflurane, desflurane): intraoperative BP and HR surge. Hold every dose on the day of surgery, not just the morning one. - **Risperidone:** EPS may increase when either dose changes in either direction. Monitor across any titration. - **Serotonergic agents** (SSRIs, SNRIs, TCAs, triptans, tramadol): serotonin syndrome in postmarketing reports only, not in the interaction table. Counsel on symptoms. --- ### **Administration** - Give 30 to 45 minutes before meals, which is a labeled instruction. - Before breakfast and before lunch; add a third dose for afternoon coverage. - Last dose before 6 p.m. for anyone whose sleep is affected. - Food has no relevant effect on absorption; a missed meal is not a reason to hold a dose. - The 5 mg tablet is not scored; a sub-5 mg step needs the 2.5 mg chewable or the oral solution ([Methylin](https://wiki.joshnp.com/link/22)). - Missed dose: give only if the next is several hours away and it is not late. Never double up. - Converting to a long-acting product ([Ritalin LA](https://wiki.joshnp.com/link/30), [Metadate CD](https://wiki.joshnp.com/link/24), [Concerta](https://wiki.joshnp.com/link/11)): never match milligrams; use that product's conversion table. - Store locked; an IR tablet is the methylphenidate form most often diverted. --- ### **Side Effects** - **Common:** tachycardia, palpitations, headache, insomnia, anxiety, hyperhidrosis, weight loss, decreased appetite, dry mouth, nausea, abdominal pain. No pediatric percentages published. - **Serious:** - Sudden death with structural cardiac disease: avoid the drug in that population - New psychosis or mania, including with no psychiatric history: consider discontinuing - Priapism, sometimes surgical, typically after a dose increase and also during drug holidays - Peripheral vasculopathy and Raynaud's with digital ulceration: assess digits each visit - Long-term growth suppression; acute angle closure glaucoma; new or worsening tics and Tourette's - Postmarketing: convulsions, choreoathetoid dyskinesia, cerebral vasculitis and hemorrhage, serotonin syndrome - Rebound irritability, hunger and tearfulness at each offset, two or three times a day: an offset effect, not an adverse reaction --- ### **Monitoring & Labs** - **Cardiovascular:** BP and HR at baseline, at every dose change, and at least every 6 months. Tachycardia and palpitations head this label's reaction list. - **Growth:** height, weight and BMI at baseline and every 6 months; failure to gain triggers interruption. - **Appetite and sleep:** at every visit and dose change; ask what time the last dose is given. - **Adherence:** confirm at every visit that the midday dose is given; a missed school dose mimics loss of efficacy. - **Psychiatric and tics:** screen for psychosis, mania, aggression, depressed mood and tics at baseline and every visit. - **Abuse and diversion:** at every refill, count the tablets rather than accepting a report, ask about sharing and selling, check the PDMP. A boxed-warning obligation. - **Laboratory:** none is required by this label. --- ### **Discontinuation & Taper** - No taper required; the label gives no tapering schedule. - Discontinue if no improvement after appropriate dose adjustment over one month. - Withdrawal after prolonged use: dysphoria, fatigue, vivid dreams, sleep change, increased appetite. - Priapism has occurred during drug holidays and on discontinuation. - Partial drug holidays are possible here: school days only, or a morning dose only at weekends. That granularity is the IR tablet's main advantage where growth limits treatment. --- ### **Pregnancy & Lactation** - **Pregnancy:** no drug-associated risk of major birth defects or miscarriage identified. Stimulant vasoconstriction may reduce placental perfusion. Weigh against untreated maternal ADHD or narcolepsy. - **Lactation:** infant dose 0.16% to 0.7% of the maternal weight-adjusted dose; undetectable in infant plasma in every reported case, including 40 mg twice daily. Not a reason to stop breastfeeding. (LactMed 2025) - **Lactation, milk supply:** prolactin falls; large doses may interfere before supply is established. Monitor the infant for agitation, insomnia and poor weight gain. (LactMed 2025) - **Exposure Registry:** National Pregnancy Registry for ADHD Medications, 1-866-961-2388, [womensmentalhealth.org/adhd-medications](https://womensmentalhealth.org/adhd-medications/). --- ### **Counseling Points** - **Counsel the family on:** - The 3 to 4 hour window: the lunchtime dose is part of the plan, not a sign the first failed. - Dosing 30 to 45 minutes before a meal, keeping the appetite trough between meals. - The last dose being before 6 p.m.; a 7 p.m. dose costs that night's sleep. - Rebound irritability and hunger two or three times a day: expected, not a reason to raise the dose. - Arranging the school dose before the first prescription is filled: nurse-administered, self-carry, or switch to a long-acting product. - The 5 mg tablet not being scored; a smaller step means a chewable or the solution, not a cut tablet. - Locked storage; sharing or selling a Schedule II medication is a felony, and the IR tablet is what peers ask for. - Bringing a teacher rating scale that separates morning from afternoon. - **Advise them to call for:** - Chest pain, fainting, or a racing heart that does not settle. - New hallucinations, or new suspicious or fearful thinking. - Numbness, coldness or colour change in fingers or toes, or a sore that will not heal. - A new or markedly worse tic, including throat clearing and blinking. - A painful erection lasting more than a few hours, including during a planned break. - Any seizure, or a jerking movement the child cannot stop. - Eye pain with blurred vision or halos around lights. - Clothes fitting more loosely, or no weight gain across a few months. --- ### **References** 1. DailyMed. Ritalin (methylphenidate hydrochloride) tablets prescribing information. Novartis Pharmaceuticals Corporation. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a 2. FDA. openFDA National Drug Code Directory, generic\_name methylphenidate. 2026. https://api.fda.gov/drug/ndc.json?search=generic\_name:%22methylphenidate%22&limit=1000 3. LactMed. Methylphenidate. Drugs and Lactation Database, NICHD. 2025. https://www.ncbi.nlm.nih.gov/books/NBK501310/ 4. American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590/ 5. AHRQ. Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents. Comparative Effectiveness Review No. 267. 2024. https://www.ncbi.nlm.nih.gov/books/NBK602989/